Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1780 | Thyroid cancer | ICEECE2012

CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo

Antonelli A. , Bocci G. , La Motta C. , Ferrari S. , Fallahi P. , Ruffilli I. , Di Domenicantonio A. , Da Settimo F. , Miccoli P.

Introduction: The antitumor activity of a novel cyclic amide, CLM94, with anti-VEGFR-2 and antiangiogenic activity, in primary anaplastic thyroid cancer (ATC) cells in vitro and in vivo, has been studied.Design and Methods: CLM94 was tested: i) in two human cell lines (HMVEC-d, dermal microvascular endothelial cells; 8305C, undifferentiated thyroid cancer) at 0.001–100 mcM; ii) in ATC cells at the concentrations of 10, 30, 50 mcM; iii)...

ea0032p1081 | Thyroid cancer | ECE2013

A novel multi-target pyrazolopyrimidine derivative with anti-neoplastic properties, CLM29, is active against medullary thyroid cancer in vitro and in vivo

Fallahi Poupak , Ferrari Silvia Martina , Bocci Guido , La Motta Concettina , Ruffilli Ilaria , Di Domenicantonio Andrea , Corrado Alda , Mancusi Caterina , Danesi Romano , Da Settimo Federico , Miccoli Paolo , Antonelli Alessandro

Introduction: CLM29, a pyrazolo[3,4-d]pyrimidine compound, inhibits several targets (including the RET tyrosine kinase, epidermal growth factor receptor, vascular endothelial growth factor receptor and has an anti-angiogenic effect). Recently it has been shown to inhibit proliferation and migration in primary papillary dedifferentiated thyroid cancer cells. The aim of this study is to evaluate the anti-tumor activity of CLM29 in medullary thyroid cancer (MTC).<p c...